- May 14, 2020
Trial Stage of Nelonicline/ABT-126
TrialStage of Nelonicline/ABT-126
ABT-126is an antipsychotic drug developed to treat Alzheimer’s disease andcognitive deficits in schizophrenia (Nelonicline| ALZFORUM,2016).The drug is currently on trial and was initially created by AbbottLaboratories based in Chicago, Illinois. This essay will describe themode of action, clinical trial stage of ABT-126 and will also discussabuse of antipsychotic drugs.
ABT-126is currently in its second phase of clinical trial. This means thatcurrent tests look at the efficacy of the drug and patients areselected randomly to receive the experimental drug. This process orphase may take several months to two years. One of the majordrawbacks associated with modern antipsychotics is their sideeffects. Research have stated that they provoke metabolic changes,alter hormones, cause weight gain and trigger extrapyramidal effects.Recent studies have even indicated that some types of antipsychoticsaccelerate brain loss and atrophy over time (Owens,2014).With ABT-126, cognitive functions are enhanced, and there are minimalside effects associated with stimulation if muscarinic acetylcholinereceptors (Gault,Ritchie, Robieson, Pritchett, Othman & Lenz, 2013).
Oneof the most commonly abused drugs in the country are antipsychotics.After reading about ABT-126 and other types of antipsychotics, I havegained more understanding of the mode of actions of some these drugs.I know understand what they do to the brain and why some peoplebehave in a certain way after using the drugs. This knowledge willhelp me when dealing with clients with specific drug addictions orabuse cases because I know understand what they are experiencing andsome of their judgment. It is beyond doubt that substance abusevictims adopt different behaviors and may be violent at times.
Fordrugs to be accepted for use by the general public, the FDA has toensure that it passes the relevant clinical trial stages and that itis safe for human and animal usage or in some cases the advantagesoutweigh the harms. The new product becomes the drug of choice fortreating the particular disease after the approval and licensing ofthe regulatory agencies. The knowledge gained this week has beenvital when it comes to the understanding of human behavior change asa result of drug abuse.
Gault,L., Ritchie, C., Robieson, W., Pritchett, Y., Othman, A., & Lenz,R. (2013). Efficacy and safety of the alpha7 agonist ABT-126 inmild-to-moderate Alzheimer`s dementia. Alzheimer`s& Dementia: The Journal of the Alzheimer`s Association, 9(4),P138.
Nelonicline| ALZFORUM.(2016). Alzforum.org.Retrieved from http://www.alzforum.org/therapeutics/nelonicline
Owens,D. C. (2014). Aguide to the extrapyramidal side-effects of antipsychotic drugs.Cambridge University Press.